Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Filtronic

    MCap

    GBP107m

    Last close

    GBP0.49

    ▲ 16.00 (48.48%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Creo Medical (AIM: CREO)

Last close As at 24/04/2024

GBP0.35

▲ 0.35 (1.01%)

Market capitalisation

GBP127m

UK-based Creo Medical focuses on the development and commercialisation of minimally invasive electrosurgical devices. Its six products in the flagship CROMA platform have all been CE marked, with five cleared by the FDA. Acquired in 2020, Albyn Medical provides Creo with profitable products and a direct salesforce in Europe.

Creo’s products are in a large and lucrative market. Conmed estimates that the GI endoscopic technologies market is worth c $3.0–3.2bn and the radiofrequency energy-based surgical device market is $2.7–2.9bn pa. Entering the robotics and laparoscopic markets further increases the scale of opportunity open to Creo.

Latest Insights

View More

Healthcare | Flash note

Creo Medical — NHS data validates Speedboat’s economic merit

Healthcare | Flash note

Creo Medical — MicroBlate Flex progresses with first robotics use

Healthcare | Flash note

Creo Medical — Solid FY23 lays the groundwork for 2024

Healthcare | Flash note

Creo Medical — UltraSlim launch – kicking off FY24 momentum
creo05
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Craig Gulliford

    CEO

  • David Woods

    Chief commercial officer

  • Richard Rees

    CFO

Balance Sheet

Forecast net debt (£m)

5.7

Forecast gearing ratio (%)

9

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (4.5) (14.9) 33.7
Relative (5.6) (19.9) 31.3
52 week high/low 48.1p/23.2p

Financials

Creo Medical has presented real-world evidence of the economic utility of its minimally invasive electrosurgical devices, based on NHS data from 130 submucosal dissection procedures using Creo’s flagship Speedboat Inject device. The data demonstrated net cash savings of £687k for the NHS trust, driven by a significant reduction in both hospitalisation and critical care costs. We believe this provides external validation to Creo’s pursuit of improving patients’ outcomes through its novel suite of devices. Speedboat Inject is currently being assessed by the National Institute for Health and Care Excellence (NICE) and we believe this data could support a positive recommendation and improved NHS adoption.

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2021A 25.2 (20.0) (29.7) (14.58) N/A N/A
2022A 27.2 (20.8) (31.0) (14.85) N/A N/A
2023E 32.8 (20.7) (24.3) (6.57) N/A N/A
2024E 40.8 (11.5) (14.8) (3.49) N/A N/A

Research

Flash note

Healthcare

Creo Medical — MicroBlate Flex progresses with first robotics use
creo05

Flash note

Healthcare

Creo Medical — Solid FY23 lays the groundwork for 2024

Healthcare

Flash note

Creo Medical — NHS data validates Speedboat’s economic merit
creo05

Flash note

Healthcare

Creo Medical — UltraSlim launch – kicking off FY24 momentum
Creo Medical_resized

Flash note

Healthcare

Creo Medical — FDA nod for UltraSlim
creo05

Flash note

Healthcare

Creo Medical — Potential UltraSlim upside with swift EU pathway

Update

Healthcare

Creo Medical — Detailed half-yearly reflecting Speedboat traction

edison tv

Healthcare

Creo Medical – executive interview with Craig Gulliford, CEO

Update

Healthcare

Creo Medical — Growth momentum with core strength
creo05

Flash note

Healthcare

Creo Medical — CE extension nearly doubles addressable GI
creo05

Flash note

Healthcare

Creo Medical — NICE to review Speedboat Inject
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free